Myricx Bio secures £90m Series A funding led by Novo Holdings and Abingworth for its N-Myristoyltransferase inhibitor (NMTi) ADC pipeline development.
UK-based Myricx Bio secured £90m ($114m) in Series A funding, led by Novo Holdings and Abingworth. The funds will be used to advance its N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) pipeline through clinical proof of concept, targeting clinically validated tumor-associated antigens. Myricx intends to establish operations in London's biotech hub and expand its management and R&D teams.
July 08, 2024
7 Articles